Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Zevra Therapeutics, Inc. (NASDAQ: ZVRA). The investigation focuses on Zevra’s executive officers and whether investor losses may be recovered under federal securities laws.

What if I purchased Zevra securities?

If you purchased Zevra securities and suffered losses on your investment, join our investigation now: Click here to join the investigation.

Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.

There is no cost or obligation to you.

Background of the investigation

On August 12, 2025, Zevra disclosed its second-quarter 2025 financial results and reported, among other things, an $11.7 million inventory write-down. Following this disclosure, Zevra’s share price declined by approximately 25%.

On November 20, 2025, Zevra announced the resignation of its Chief Financial Officer. Following this announcement, Zevra’s stock price declined approximately 18% over the following trading days.

In light of these disclosures, Johnson Fistel is investigating whether Zevra complied with the federal securities laws. If you suffered losses from your investment in Zevra stock, contact Johnson Fistel.

About Johnson Fistel, PLLP | Top Law Firm – Securities Fraud & Investor Rights

Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit www.johnsonfistel.com.

Achievements

In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. This recognition reflects the firm’s effectiveness in advocating for investors, having recovered approximately $90,725,000 for aggrieved clients in cases where it served as lead or co-lead counsel. This marks the eighth time the firm has been recognized as a top plaintiffs’ securities law firm in the United States, based on the total dollar value of final recoveries.

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260218343865/en/

SAN DIEGO – Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Zevra Therapeutics, Inc. (NASDAQ: ZVRA). The investigation focuses on Zevra’s executive officers and whether investor losses may be recovered under federal securit